- Home
- AARD vs ACHV Comparison
AARD vs ACHV Comparison
Compare AARD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- ACHV
- Stock Information
- Founded
- AARD 2017
- ACHV N/A
- Country
- AARD United States
- ACHV United States
- Employees
- AARD N/A
- ACHV N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AARD Health Care
- ACHV Health Care
- Exchange
- AARD Nasdaq
- ACHV Nasdaq
- Market Cap
- AARD 186.3M
- ACHV 153.8M
- IPO Year
- AARD 2025
- ACHV N/A
- Fundamental
- Price
- AARD $16.08
- ACHV $3.15
- Analyst Decision
- AARD Strong Buy
- ACHV Strong Buy
- Analyst Count
- AARD 7
- ACHV 2
- Target Price
- AARD $31.43
- ACHV $16.00
- AVG Volume (30 Days)
- AARD 238.4K
- ACHV 845.2K
- Earning Date
- AARD 11-14-2025
- ACHV 11-06-2025
- Dividend Yield
- AARD N/A
- ACHV N/A
- EPS Growth
- AARD N/A
- ACHV N/A
- EPS
- AARD N/A
- ACHV N/A
- Revenue
- AARD N/A
- ACHV N/A
- Revenue This Year
- AARD N/A
- ACHV N/A
- Revenue Next Year
- AARD N/A
- ACHV N/A
- P/E Ratio
- AARD N/A
- ACHV N/A
- Revenue Growth
- AARD N/A
- ACHV N/A
- 52 Week Low
- AARD $4.88
- ACHV $1.84
- 52 Week High
- AARD $19.58
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- AARD 79.19
- ACHV 56.75
- Support Level
- AARD $10.75
- ACHV $3.07
- Resistance Level
- AARD $14.32
- ACHV $3.21
- Average True Range (ATR)
- AARD 1.07
- ACHV 0.14
- MACD
- AARD 0.58
- ACHV 0.01
- Stochastic Oscillator
- AARD 95.99
- ACHV 77.55
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.